How much of the $100 million authorization has been used so far?

The filing does not disclose how much of the authorization has been exercised or the remaining balance as of the August 4, 2026 disclosure date. No execution details are provided.

How will LeMaitre repurchase shares—open market, accelerated repurchase, or another method?

The filing does not specify an execution mechanism. The company has not committed to Rule 10b-18 open-market purchases, an accelerated share repurchase agreement, or any other particular method.

Does this buyback compete with dividends for cash?

LeMaitre announced both a quarterly dividend of $0.25 per share and this repurchase authorization, suggesting the company believes its $376 million cash balance and operating cash flow provide room for both. Repurchases are discretionary and may be scaled back if needed.

Why did LeMaitre announce this buyback in an earnings release rather than a formal 8-K filing?

The authorization was disclosed in the Q2 2026 earnings press release, which is attached as Exhibit 99.1 to the 8-K filed on August 4, 2026. This is a common disclosure practice; the formal SEC filing (8-K) triggers the regulatory obligation to disclose material corporate actions.

How does this $100 million authorization compare to LeMaitre's market capitalization?

The filing does not provide the current stock price or market cap. However, with annual revenue guidance of $274–$278 million and $376 million in cash, a $100 million repurchase represents a meaningful but not outsized allocation of capital, consistent with mid-cap medical-device company practice.

LMAT 8-K Filed 2026-08-04 New authorization

LeMaitre Vascular authorizes $100M share repurchase program

Board approval on Feb. 19, 2026; program runs through Feb. 18, 2027; execution mechanism not specified.

Authorization$100M

MechanismNot specified

What the filing says

LeMaitre Vascular's Board of Directors authorized a share-repurchase program of up to $100 million on February 19, 2026. The program is set to conclude on February 18, 2027, unless extended by the Board. The company retains full discretion to suspend or discontinue the program at any time.

This authorization was disclosed in the company's Q2 2026 earnings release, filed as an 8-K exhibit on August 4, 2026. No specific execution mechanism (such as open-market Rule 10b-18 purchases, accelerated share repurchase, or 10b5-1 trading plan) is specified in the filing. The filing provides no detail on shares repurchased to date under the authorization or remaining balance.

LeMaitre reported strong Q2 2026 results with sales of $70.4 million (+10% organic) and cash and equivalents of $376.2 million, providing financial flexibility for capital allocation including share repurchases and dividends. The company also declared a quarterly dividend of $0.25 per share in conjunction with this announcement.

On February 19, 2026, the Company's Board of Directors authorized the repurchase of up to $100.0mm of the Company's common stock. The repurchase program may be suspended or discontinued at any time and will conclude on February 18, 2027, unless extended by the Board. — LEMAITRE VASCULAR INC 8-K filing · View on SEC EDGAR →

What this means

LeMaitre's $100 million repurchase authorization represents a discretionary capital return option for the company as it pursues its growth strategy, particularly the Artegraft international expansion mentioned in CEO commentary. At current trading levels and with the company carrying $376 million in cash, the repurchase program would not materially constrain liquidity or debt-service capacity. The filing provides no execution details, leaving timing and pace entirely to management discretion. With a one-year authorization period and no mandatory minimum repurchases, the program is best viewed as a tool to manage share count if the stock trades at attractive valuations—not as a commitment to a fixed capital return amount.

Frequently asked questions

When did LeMaitre authorize this $100 million buyback, and when does it expire?: The Board of Directors authorized the program on February 19, 2026, and it will conclude on February 18, 2027, unless extended by the Board. The company may suspend or discontinue repurchases at any time within that window.
How much of the $100 million authorization has been used so far?: The filing does not disclose how much of the authorization has been exercised or the remaining balance as of the August 4, 2026 disclosure date. No execution details are provided.
How will LeMaitre repurchase shares—open market, accelerated repurchase, or another method?: The filing does not specify an execution mechanism. The company has not committed to Rule 10b-18 open-market purchases, an accelerated share repurchase agreement, or any other particular method.
Does this buyback compete with dividends for cash?: LeMaitre announced both a quarterly dividend of $0.25 per share and this repurchase authorization, suggesting the company believes its $376 million cash balance and operating cash flow provide room for both. Repurchases are discretionary and may be scaled back if needed.
Why did LeMaitre announce this buyback in an earnings release rather than a formal 8-K filing?: The authorization was disclosed in the Q2 2026 earnings press release, which is attached as Exhibit 99.1 to the 8-K filed on August 4, 2026. This is a common disclosure practice; the formal SEC filing (8-K) triggers the regulatory obligation to disclose material corporate actions.
How does this $100 million authorization compare to LeMaitre's market capitalization?: The filing does not provide the current stock price or market cap. However, with annual revenue guidance of $274–$278 million and $376 million in cash, a $100 million repurchase represents a meaningful but not outsized allocation of capital, consistent with mid-cap medical-device company practice.

authorization medical-device rule-10b-18-not-specified mid-cap one-year-program

Source. This editorial summary is based on the SEC filing linked above. BuybackStocks aggregates and editorializes publicly available SEC EDGAR filings. Not investment advice. Past authorization announcements do not guarantee future repurchase activity or share price performance. See our full disclosures policy.